Which imaging modality is superior for prediction of response to neoadjuvant chemotherapy in patients with triple negative breast cancer?

Authors

Jordan J. Atkins, Washington University School of Medicine in St. Louis
Catherine M. Appleton, Washington University School of Medicine in St. Louis
Carla S. Fisher, University of Pennsylvania
Feng Gao, Washington University School of Medicine in St. LouisFollow
Julie A. Margenthaler, Washington University School of Medicine in St. Louis

Journal

Journal of Oncology

Publication Date

2013

Inclusive Pages

1-7

Document Type

Open Access Publication

DOI

10.1155/2013/964863

Rights and Permissions

Jordan J. Atkins, Catherine M. Appleton, Carla S. Fisher, Feng Gao, and Julie A. Margenthaler, “Which Imaging Modality Is Superior for Prediction of Response to Neoadjuvant Chemotherapy in Patients with Triple Negative Breast Cancer?,” Journal of Oncology, vol. 2013, Article ID 964863, 7 pages, 2013. doi:10.1155/2013/964863

Recommended Citation

Atkins, Jordan J.; Appleton, Catherine M.; Fisher, Carla S.; Gao, Feng; and Margenthaler, Julie A., "Which imaging modality is superior for prediction of response to neoadjuvant chemotherapy in patients with triple negative breast cancer?." Journal of Oncology. 1-7. (2013).
https://digitalcommons.wustl.edu/open_access_pubs/1285